慢性C型肝炎治療的新展望

Novel Perspectives for Therapy of Chronic Hepatitis C

10.6200/TCMJ.2007.4.9.11

林聰蓉(Tsung-Jung Lin)；廖麗瑛(Li-Ying Liao)；王鐘貴(Chung-Kwe Wang)

慢性C型肝炎 ； 長效型干擾素 ； 雷巴威林Ribavirin ； 蛋白酶抑制劑 ； 聚合酶抑制劑 ； 干擾素誘導劑 ； chronic hepatitis C ； peginterferon ； ribavirin ； protease inhibitor ； polymerase inhibitor ； interferon inducer

北市醫學雜誌

4卷9_S期（2007 / 12 / 01）

873 - 879

繁體中文

最近幾年來，慢性C型肝炎的標準治療－併用長效型干擾素α與口服雷巴威林(Ribavirin)，已將治療效果提高到六成左右，台灣更有將近七成的持續病毒反應率。儘管如此，仍有部分病人無法達到療效，有些病人因副作用而必須降低劑量或無法接受治療。因此，許多新的抗病毒策略正在臨床試驗中，如C型肝炎病毒蛋白酶抑制劑、聚合酶抑制劑、干擾素誘導劑、與副作用較低之雷巴威林類似(Ribavirin-like)藥物等。未來最有效的慢性C型肝炎治療方式，可能是同時使用幾種藥物，而不只是併用長效型干擾素α與口服雷巴威林(Ribavirin)。

In recent years, the standard therapy for chronic hepatitis C is the combination therapy with peginterferon α and ribavirin. The combination results in a sustained eradication of hepatitis C virus and a long-term remission of the disease in about 60% of patients in Western and 70% in Taiwan. However, current treatment is not ideal since it is not effective in more than one-third of chronic hepatitis C patients. Furthermore, it is not suitable for all patients because of significant side effects. Therefore, new treatment strategies are being developed including hepatitis C virus protease inhibitors, polymerase inhibitors, interferon inducers, or less-toxic ribavirin-like agents. Many new antiviral compounds are now in preclinical and clinical trials. In the future, the optimal therapies of chronic hepatitis C may employ several kinds of agents together rather than the simple combination of peginterferon α and ribavirin.